Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study

  • Yadav, Prasant (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Mir, Rashid (Prince Fahad Bin Sultan Scientific Chair, Faculty of Applied Medical Sciences, Tabuk University) ;
  • Nandi, Kajal (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Javid, Jamsheed (Prince Fahad Bin Sultan Scientific Chair, Faculty of Applied Medical Sciences, Tabuk University) ;
  • Masroor, Mirza (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Ahmad, Imtiyaz (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Zuberi, Mariyam (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Kaza, RCM (Dept. of Surgery, Maulana Azad Medical College and Associated Hospitals) ;
  • Jain, SK (Dept. of Surgery, Maulana Azad Medical College and Associated Hospitals) ;
  • Khurana, Nita (Dept. of Pathology, Maulana Azad Medical College and Associated Hospitals) ;
  • Ray, Prakash Chandra (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Saxena, Alpana (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Worldwide, breast cancer is the most common cancer among women and is a leading cause of cancer death. In the present study, we investigated the NQO1 C609T genotypic and allelic distribution in north Indian breast cancer patients. Materials and Methods: The genotypic distribution of the NQ01 C609T polymorphism was assessed in 100 invasive ductal carcinoma (IDC) breast cancer patients and 100 healthy controls using allele specific PCR (AS-PCR). Results: A lower frequency of the CC genotype was found in breast cancer patients (24%) than in the controls. On the other hand, TT genotype frequency was also found to be higher in female healthy controls (32%) than the female breast cancer patients (20%). The frequencies of all three genotypes CC, CT, TT in patients were 24%, 56% and 20% and in healthy controls 50%, 22% and 32% respectively. We did not find any significant correlation between the NQO1 C609T polymorphism and age group, grading, menopausal status and distant metastasis. A less significant association was found between the NQ01 C609T polymorphism and the stage of breast cancer (X2=5.931, P=0.05). Conclusions: The present study shows a strong association between NQO1 C609T polymorphism with the breast cancer risk in the north Indian breast cancer patients so that possible use as a risk factor should be further expel.

Keywords

References

  1. Ambrosone CB (2000). Oxidants and antioxidants in breast cancer. Antioxid Redox Signal, 2, 903-17. https://doi.org/10.1089/ars.2000.2.4-903
  2. di Martino E1, Hardie LJ, Wild CP, et al (2007). "The NAD(P) H:quinone oxidoreductase I C609T polymorphism modifies the risk of barrett esophagus and esophageal adenocarcinoma." Genetics Med, 9, 341-7. https://doi.org/10.1097/GIM.0b013e3180654ccd
  3. Fagerholm R, Hofstetter B, Tommiska J, et al (2008). NAD(P) H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet, 40, 844-53. https://doi.org/10.1038/ng.155
  4. Hamajima N, Matsuo K, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
  5. Jana Sarmanova, Simona Su sova, Ivan Gut, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Human Genetics, 12, 848-54. https://doi.org/10.1038/sj.ejhg.5201249
  6. Jay H. Fowke, Xiao-Ou Shu, Qi Dai, et al (2004). Genetic Polymorphisms Modification by NAD(P)H:Quinone oxoreductase (NQO1) oral contraceptive use and breast cancer risk. cancer epidemiol biomarkers prev, 13, 1308-15.
  7. Kuehl BL, Paterson JW, Peacock JW, et al (1995). Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer, 72, 555-561. https://doi.org/10.1038/bjc.1995.373
  8. Lewis SJ, NM Cherry (2001). Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-183. https://doi.org/10.1016/S0169-5002(01)00243-4
  9. Menzel HJ, J Sarmanova, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independentpopulations. Br J Cancer, 90, 1989-94. https://doi.org/10.1038/sj.bjc.6601779
  10. Moran JL, Siegel D, Ross D (1999). A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA, 96, 8150-5. https://doi.org/10.1073/pnas.96.14.8150
  11. Menzel HJ, J Sarmanova (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94. https://doi.org/10.1038/sj.bjc.6601779
  12. Nowell SA, Ahn J, Ambrosone CB, et al (2004). Gene-nutrient interactions in cancer etiology. Nutr Rev, 62, 427-38. https://doi.org/10.1111/j.1753-4887.2004.tb00014.x
  13. Niwa Y, K Hirose (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecologic Oncol 96, 423-9. https://doi.org/10.1016/j.ygyno.2004.10.015
  14. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a huge review. Genet Med, 4, 62-70 https://doi.org/10.1097/00125817-200203000-00003
  15. Rauth AM, Goldberg Z, Misra V (1997) DT-diaphorase: possible roles in cancer. chemotherapy and carcinogenesis. Oncol Res, 9, 339-49.
  16. Ross D, Traver RD, Siegel D, et al (1996). A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer, 74, 995-6. https://doi.org/10.1038/bjc.1996.477
  17. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113-21. https://doi.org/10.1097/00008571-199902000-00015
  18. Siegel D, Anwar A,Winski SL, Kepa JK, Dowd KL (2001). Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8. https://doi.org/10.1124/mol.59.2.263
  19. Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011) Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers, 15, 343-349. https://doi.org/10.1089/gtmb.2010.0197
  20. Traver RD, Siegel D, Beall HD, et al (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75. https://doi.org/10.1038/bjc.1997.11
  21. Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cyclingof stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys, 346, 180-6. https://doi.org/10.1006/abbi.1997.0306